International Journal of Molecular Imaging
Volume 2014 (2014), Article ID 507012, 10 pages
http://dx.doi.org/10.1155/2014/507012

Research Article

Ex Vivo Characterization of a Novel Iodine-123-Labelled Aminomethylchroman as a Potential Agonist Ligand for SPECT Imaging of Dopamine D2/3 Receptors

Jan-Peter van Wieringen,¹ Kora de Bruin,¹ Henk M. Janssen,² P. Michel Fransen,² Anton G. M. Janssen,³ Peter A. van Doremalen,³ Martin C. Michel,⁴ Philip H. Elsinga,⁵ and Jan Booij¹

¹Department of Nuclear Medicine, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, Netherlands
²SyMO-Chem BV, Den Dolech 2, 5612 AZ Eindhoven, Netherlands
³GE Healthcare, De Rondom 8, 5612 AP Eindhoven, Netherlands
⁴Department of Pharmacology, Johannes Gutenberg University, Obere Zahlbacher Straße 67, 55101 Mainz, Germany
⁵Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713 GZ Groningen, Netherlands

Received 29 July 2014; Revised 18 November 2014; Accepted 27 November 2014; Published 25 December 2014

Academic Editor: Adriaan A. Lammertsma

Copyright © 2014 Jan-Peter van Wieringen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract.

For imaging of dopamine D2/3 receptors, agonist tracers are favoured over antagonists because they are more sensitive to detection of dopamine release and because they may selectively label the high-affinity receptor state. We have developed novel D2/3 receptor selective agonists that can be radiolabelled with [¹²³I], which label is advantageous over most other labels, such as carbon-11, as it has a longer half-life. Particularly, we considered (R) N-[7-hydroxychroman-2-yl]-methyl 4-iodobenzyl amine (compound 1) as an attractive candidate for development as it shows high binding affinity to D2/3 receptors in vitro, and here we report on the characterization of this first [¹²³I]-labelled D2/3 receptor agonist radiopharmaceutical intended for SPECT imaging. The appropriate tin precursor for [¹²³I]-1 was developed and was successfully radiolabelled with iodine-123 giving a moderate yield (30–35%) and a good purity (>95%) for [¹²³I]-1. In biodistribution experiments in Wistar rats intravenous injection of [¹²³I]-1 resulted in a fast brain uptake, where the observed binding in the D2/3 receptor-rich striatum was slightly higher than that in the cerebellum 30 min to 4 h p.i. Storage phosphor imaging experiments, however, did not show specific D2/3 receptor binding. In conclusion, despite promising in vitro data for 1, neither specific ex vivo binding nor high signal-to-noise ratios were found in rodents for [¹²³I]-1.

1. Introduction

A disturbed dopamine system plays a role in the etiology of several neuropsychiatric disorders, including Parkinson’s disease (PD) [1], schizophrenia [2], and drug addiction [3]. The prevalence of PD and schizophrenia is about 1% [4], while the prevalence of addiction (including alcoholism) is much higher [5], leading to a large disease burden.

Dopamine receptors are part of the superfamily of G-protein coupled receptors (GPCRs) and can, based on their action on adenylyl cyclase (AC), be divided into 2 subfamilies. After activation, the dopamine D₁-like (D₁ and D₅) receptors stimulate AC to produce the second messenger cyclic adenosine monophosphate (cAMP) while the D₂-like (D₂, D₃, and D₄) receptors inhibit this enzyme [6, 7]. Like other GPCRs they demonstrate interconvertible high- and low-affinity states for agonists in vitro [8–11]. The D2/3 high-affinity state represents the active form of the receptor [12]. Changes in the density of D2/3 receptors in this high-affinity state seem to be more important for the pathophysiology of neuropsychiatric disorders than those of the total receptor density; in several animal models increases in striatal D2/3 high-affinity receptors of up to 9-fold compared to control animals were found while the total receptor number did not increase or even showed a small decrease [13].

Because agonists are selective for the high-affinity state they can distinguish a shift in receptors from low- to high-affinity states. Antagonists fail to do this because they bind with equal affinity to both the low- and high-affinity states of a receptor [14]. Several compounds of different chemical classes have been synthesized and characterized as agonist positron emission tomography (PET) radioligands (for review see [15]), which offers the potential to image the D2/3 high-affinity receptor in the human brain. Of them only the aporphines [¹¹C]NPA (N-propylnorapomorphine), [¹¹C]MNPA (2-methoxy-N-propylnorapomorphine), and the naphthoxazine [¹¹C]PHNO (4-propyl-9-hydroxynaphthoxazine) are currently being evaluated in man [16–18]. [¹¹C]PHNO and [¹¹C]NPA showed a better sensitivity to detection of dopamine release than antagonist radiopharmaceuticals in human brain [19, 20] which confirmed earlier findings of animal studies [21, 22].

As of yet only [¹¹C]-labelled agonist dopamine D2/3 receptor PET ligands have been developed successfully in humans. But because of the short half-life of [¹¹C] (20.4 min), these radiopharmaceuticals have the disadvantage that they can only be used when a cyclotron is on-site or nearby. This expensive device is available in only the minority of hospitals. Interestingly, a [¹⁸F]-labelled aporphine ([¹⁸F]MCL-524) has recently been evaluated successfully in monkeys [23]. Compared to [¹¹C]-labelled tracers, this tracer offers the advantage of a longer half-life (109.8 min), but studies in humans have not yet been reported, and no agonist SPECT tracer for imaging dopamine D2/3 receptors has been developed yet. Consequently, it is rational to develop [¹²³I]-labelled (half-life 13.2 h) agonists dopamine D2/3 tracers for single photon emission computed tomography (SPECT) imaging because [¹²³I] coupled ligands are better available because they can be distributed from the site where they are synthesized. SPECT cameras are available in the vast majority of hospitals, and because iodine-123 has a substantial half-life, studies with [¹²³I]-labelled ligands can also be better scheduled than studies using [¹¹C]-labelled tracers. Therefore we have synthesized and explored a novel series of potential dopamine agonists [24] that are suitable for PET or SPECT imaging. More specifically, we have developed a series of aminomethylchromans (AMCs), a class of molecules first introduced by Mewshaw et al. [25], and have found that most of these AMCs were agonists at D2/3 receptors and showed high-affinity and selectivity for these versus other dopamine receptor subtypes. Additionally, some of the presented compounds were successfully labelled with fluorine-18 and were subsequently used in small-animal studies [24]. These findings suggested that a particular synthesized iodide AMC-compound, compound 1 (see Scheme 1), is an attractive candidate for labelling with iodine-123, as this compound 1 shows a high-affinity and selectivity for D2/3 receptors in their high-affinity state, a proper lipophilicity, and a high degree of agonism (see Section 2 for details). Furthermore, structure 1 is an aryl-iodide, so it should permit the synthesis of a trialkyltin precursor that is suitable as a substrate for oxidative electrophilic radioiodination. In this study, we present the ex vivo characterization of compound 1. After labelling with iodine-123, classic biodistribution studies as well as storage phosphor imaging studies were performed in rats to test the suitability of this novel tracer for SPECT imaging.

Scheme 1: Compilation of the applied chemical conversions. Preparative synthesis includes the following: (i) hexa-n-butylditin, Pd(PPh₃)₄, and dioxane, 100°C. “Cold” labelling tests include the following: (ii) NaI, H₂O₂, and acetic acid/acetate buffer, rt. Radiolabelling includes the following: (iii) [¹²³I]-NaI, H₂O₂, and HOAc/NH₄OAc buffer and (iv) H₂SO₄, ethanol, and heat.

2. Materials and Methods

Reagents, chemicals, materials, and solvents were obtained from commercial sources and were used as received: Biosolve, Merck for solvents, Cambridge Isotope Laboratories for deuterated solvents, and Aldrich, Acros, ABCR, Merck, or Fluka for chemicals, materials, and reagents. All solvents were of analytical grade (AR) quality. Moisture or oxygen-sensitive reactions were performed under an atmosphere of dry N₂ or argon. The syntheses of compound 1 and its MOM (CH₃–O–CH₂–)-protected derivative (compound 2) (see Scheme 1) have been reported previously [24]. Analytical thin layer chromatography (TLC) was performed on Kiesel gel F-254 precoated silica plates. Normal phase column chromatography was carried out on flash silica gel (40–63 μm mesh) or regular silica gel (60–200 μm), both acquired from Screening Devices B.V.

¹H-NMR and ¹³C-NMR spectra were recorded on Varian Mercury (400 MHz for ¹H-NMR, 100 MHz for ¹³C-NMR) spectrometers at 298 K. Chemical shifts are reported in ppm downfield from tetramethylsilane (TMS) for ¹H NMR and applying deuterated chloroform (CDCl₃) or other deuterated solvents as internal reference for ¹³C NMR.

HPLC-PDA/MS analyses, as used for the characterization of precursors 3 and 4 as well as in the labeling tests, were performed on a Shimadzu LC-10 AD VP series LC coupled to a photodiode array (PDA) detector (Finnigan Surveyor PDA Plus Detector, Thermo Electron Corporation) and an ion-trap detector (LCQ Fleet, Thermo Scientific). Analyses were executed at 298 K using an Alltech Alltima HP C18 3 μ column using an injection volume of 1–4 μL, a flow rate of 0.2 mL min⁻¹, and a MeCN in H₂O gradient (2-minute isocratic conditions at 5% MeCN, followed by a 10-minute gradient to 100% MeCN, where both MeCN and H₂O contain 0.1% formic acid).

[¹²³I]-NaI was produced using the cyclotron at the Eindhoven site of GE Healthcare, Netherlands, and was isolated in a 0.05 M NaOH aqueous solution. Other reagents, chemicals, materials, and solvents were obtained from commercial sources and were used as received. For the separation and isolation of [¹²³I]-1 reversed phase chromatography was performed on a Waters Spherisorb S5ODS2 ( mm) applying a Varian Bond Elut C18 (1 mL 100 mg) cartridge. This HPLC system was also used to assess the yield and radiochemical purity of the end product, applying a NaI-scintillation detector.

2.1. In Vitro Binding Data and Physiochemical Characteristics on Compound 1

We have previously presented the in vitro data of a new series of AMCs, including those for the unlabelled compound 1, that is, (R) N-[7-hydroxychroman-2-yl]-methyl 4-iodobenzyl amine [24]. See Scheme 1 for the molecular structure of 1. Briefly, compound 1 showed a high in vitro affinity (mean Ki of 3.79 nM and 51.8 nM for D₂ high and D₂ low, resp.) and selectivity for the D2/3  receptorhigh over D₁-like receptors (mean Ki for D₁ receptor of 8.67 μM). Also, the compound showed agonism for the D₂ receptor (pEC50: cAMP: , Emax: (% of dopamine)) and a calculated lipophilicity of (using ClogP software). For all details with respect to the performed experiments and assays on compound 1, the reader is referred to our earlier work [24], wherein compound 1 is numbered as compound 11a.

2.2. Synthetic Procedures

2.2.1. (R) N-[7-Hydroxychroman-2-yl]-methyl 4-(Tri-n-butyltin)-benzyl Amine (Precursor 3)

(R) N-[7-Hydroxychroman-2-yl]-methyl 4-iodobenzyl amine (1) (50 mg, 0.127 mmol), palladium tetrakis (7.3 mg, 6.3 micromol, 0.05 moleqs), hexa-n-butylditin (147 mg, 0.253 mmol, 2 moleqs), and dioxane (1 mL) were stirred at 100°C for 16 hours while the reaction mixture was kept under an argon atmosphere. According to HPLC-MS analysis no iodocompound 1 was present any more. The mixture was cooled down to room temperature and was filtered over Celite and the filtrate was evaporated. Dissolution in CHCl₃ was followed by washing of the organic layer with a 5% KF solution in water to remove the Bu₃SnI byproduct. The CHCl₃ solution was evaporated to dryness and the crude product was purified by silica column chromatography, eluting first with CHCl₃/TEA (99/1) and then with CHCl₃/TEA/MeOH (98/1/1). Yield: 27 mg (38%).

¹H NMR (400 MHz, CDCl₃, δ): 7.45 (d, J = 7.8 Hz, Ar H, 2H), 7.35 (d, J = 7.8 Hz, Ar H, 2H), 6.8 (d, J = 8.2 Hz, Ar H, 1H), 6.35 (m, Ar H, 2H), 4.05 (m, CHO, 1H), 3.95 (d, J = 13.3 Hz, NCH ′H′′Ph, 1H), 3.85 (d, J = 13.3 Hz, NCH′H ′′Ph, 1H), 2.85 (m, CHN, 1H), 2.75 (m, CHN, 1H), 2.7-2.6 (m, CH, 2H), 1.85 (m, CH, 1H), 1.65 (m, CH, 1H), 1.55 (m, CH₂, 6H), 1.3 (m, CH₂, 6H), 1.05 (m, CH₂, 6H), 0.9 (t, CH₃, J = 7.2 Hz, 9H). ¹³C NMR (100 MHz, CDCl₃, δ): 156.3, 154.5, 141.2 ( = 384, 367 Hz), 137.7 ( = 10 Hz), 136.8 ( = 31 Hz), 130.0, 128.2 ( = 41 Hz), 112.5, 109.2, 103.4, 74.2, 54.1, 53.7, 29.1 ( = 20 Hz), 27.4 ( = 57 Hz), 26.3, 23.7, 13.7, 9.6 ( = 340, 325 Hz). According to HPLC-PDA/MS, compound 3 was pure as in the chromatogram the product peak was dominant (>95%). HPLC-MS: m/z = 560.3 [M+H]⁺, (calcd 558.38 for C₂₉H₄₅NO₂Sn).

2.2.2. (R) N-[7-(Methoxymethoxy)chroman-2-yl]methyl 4-(Tri-n-butyltin)-benzyl Amine (Precursor 4)

(R) N-[7-(Methoxymethoxy)chroman-2-yl]-methyl 4-iodobenzyl amine (2) (90 mg, 0.205 mmol), palladium tetrakis (11.8 mg, 10.2 micromol, 0.05 moleqs), and hexabutylditin (237 mg, 0.409 mmol, 2 moleqs) were stirred in dioxane (1 mL) at 100°C for 4 hours, while the mixture was kept under an argon atmosphere. According to HPLC-MS no iodocompound 2 was present any more. The mixture was cooled down to room temperature and filtered over Celite. The filtrate was evaporated, and the crude product was dissolved in CHCl₃. Washing with a 5% KF solution in water was performed so as to remove Bu₃SnI byproduct. Finally, the CHCl₃ layer was concentrated and the residue was purified by silica column chromatography eluting with CHCl₃/TEA (99/1). Yield: 50 mg (41%).

¹H NMR (400 MHz, CDCl₃, δ): 7.45 (d, J = 7.9 Hz, Ar H, 2H), 7.35 (d, J = 7.9 Hz, Ar H, 2H), 6.9 (d, J = 8.2 Hz, Ar H, 1H), 6.53 (m, Ar H, 2H), 5.1 (s, OCH₂O, 2H), 4.15 (m, CHO, 1H), 3.8 (s, NCH₂Ph, 2H), 3.45 (s, OCH₃, 3H), 2.9–2.6 (m, CH, 4H), 1.95 (m, CH, 1H), 1.75 (m, CH and NH, 2H), 1.55 (m, CH₂, 6H), 1.3 (m, CH₂, 6H), 1.05 (m, CH₂, 6H), 0.9 (t, J = 7.3 Hz, CH₃, 9H). ¹³C NMR (100 MHz, CDCl₃, δ): 156.4, 155.3, 140.2 ( = 390, 372 Hz), 139.9 ( = 10 Hz), 136.6 ( = 31 Hz), 129.9, 127.7 ( = 41 Hz), 115.5, 108.9, 104.4, 94.5, 75.4, 55.9, 54.0, 53.7, 29.1 ( = 21 Hz), 27.4 ( = 57 Hz), 25.6, 24.1, 13.7, 9.6 ( = 340, 325 Hz). According to HPLC-PDA/MS, compound 4 was pure as in the chromatogram the product peak was dominant (>95%). HPLC-MS: m/z = 604.3 [M+H]⁺, (calcd 603.3 for C₃₁H₄₉NO₃Sn).

2.3. Labelling Tests

2.3.1. “Cold” Iodination of the Unprotected Phenol Precursor 3

Tri-n-butyltin precursor 3 (1 mg, 1.79 μmol, 12.3 moleqs) was dissolved in ethanol (1 mL) and an acetic acid buffer solution (10 mL of a pH = 4 buffer prepared by mixing 3.4 g NH₄OAc and 8.2 g glacial acetic acid in 1 L of water). Next, NaI was added (721 microliters of a stock solution of 30 mg NaI/L 0.05 M NaOH; 0.145 μmol NaI), and finally a 30% solution of H₂O₂ in water (1 mL) was added. After 1 hour of stirring at room temperature, the reaction mixture was analyzed by HPLC-MS. Besides the starting material 3 that was observed most abundantly, two main products were found where these two compounds had the same molecular weight of 684.3 and showed almost identical retention times. Given this molecular weight, we attribute these two compounds to molecules 5 and 6; see Scheme 1, where iodination has taken place at the (activated) ortho positions relative to the phenol hydroxy group. Furthermore, destannylated product, that is, (R) N-[7-hydroxychroman-2-yl]-methyl benzyl amine, was traced, while the desired labelled material 1 was hardly traced at all.

2.3.2. “Cold” Iodination of the MOM-Protected Precursor 4

Tri-n-butyltin precursor 4 (2 mg, 3.32 μmol, 11.4 moleqs) was dissolved in ethanol (2 mL) and an acetic acid buffer (20 mL of a buffer solution prepared from 3.4 g NH₄OAc and 8.2 g glacial acetic acid in 1 L of water). Next, NaI was added (1442 μL of a solution prepared from 30 mg of NaI in 1 L 0.05 M NaOH solution in water; 0.29 μmol NaI), and finally a 30% H₂O₂ solution in water (2 mL) was added. The reaction was left to stir for 1 hour at room temperature. According to HPLC-MS analysis, the starting compound 4 was mostly present, as well as the desired iodinated MOM-protected product 2. No other products other than 2 were traced, particularly not those that indicate ortho iodination, that is, products with a molecular weight of 728.3. Even after addition of another portion of NaI (0.4 mg, 2.66 μmol, 0.8 moleqs) in 1 mL of water, and after further stirring of the reaction mixture for 3 hours, products other than 2 were not traced.

2.4. Radiolabelling

2.4.1. The Radiosynthesis of [¹²³I]-1

Precursor compound 4 was dissolved in ethanol at a concentration of 1 mg/mL. Typically, 50 to 80 μL of this solution (50–80 μg 4) and 100–300 μL of a 0.05 M NaOH solution containing the required amount of [¹²³I]-NaI (1.48–5.18 GBq/40–140 mCi at the time of handling (TOH); specific activity 185 MBq/nmol (5000 Ci/mmol at reference time)) were mixed in about 0.5 mL of a pH = 4 NH₄OAc/HOAc buffer solution (HOAc 0.13 M and NH₄OAc 0.044 M; prepared by adding 1.7 gr NH₄OAc and 4 mL of glacial acetic acid to 500 mL of water). To this buffered solution, 50 μL of a 30 v/v% H₂O₂ aqueous solution and finally 50 μL of a 25 v/v% sulfuric acid aqueous solution were added. After 5 to 10 minutes the reaction mixture was passed through a C18 SPE cartridge. Rinsing with water to remove H₂O₂ and salts was followed by recovery of the reaction product [¹²³I]-2 in 1 mL of ethanol. Next, a small volume of a 25 v/v% sulfuric acid aqueous solution (250–300 μL) was added and the mixture was heated in a stream of hot air for 10 min to achieve >95% deprotection of the MOM group. A second C18 SPE cartridge was used to isolate the deprotected product [¹²³I]-1. Since in the MOM-deprotection step radioiodinated side products appeared, the crude product was purified using a HPLC separation step applying isocratic conditions (eluent: ethanol/0.2 M NaOAc = 65/35 (v/v)). The purified product was isolated from the HPLC eluent by using a third C18 SPE cartridge, again collecting the product in ethanol. Finally, the ethanol solvent was removed by evaporation and the product was redissolved in an isotonic pH = 4.8 NaOAc buffer containing 8–10 v/v% ethanol. Typically, the overall yield of the process was 30–35% with a final radiochemical purity exceeding 95%. The radiochemical purity and identity were determined using HPLC (the same system as used for purification); the yield was determined using an ionization chamber.

2.5. Animal Studies

The performed experiments are in agreement with The Dutch Experiments on Animals Act (1977) and were approved by the Animal Ethics Committee (AMC, Amsterdam, Netherlands).

2.5.1. Biodistribution Studies in Rats

[¹²³I]-1 (SA ≥ 37 MBq/nmol) was received after radiolabelling in an isotonic acetate (9% EtOH) buffer (pH 4.8). The solution was passed through a membrane filter (0.2 μm) and was diluted to the proper concentrations. Male Wistar rats (approximately 250 g body weight, obtained from Harlan/Charles River, Zeist, Netherlands) received an intravenous injection in the tail vein of approximately 3.7 MBq/0.4 mL buffer of [¹²³I]-1 under O₂/CO₂ anaesthesia. Distribution to the tissue was measured 15 min, 30 min, and 1, 2, 3, 4, and 24 h after the injection to determine the time course of uptake in several organs, including the brain. Four rats were killed at each time point via bleeding by heart puncture (to minimize contribution of blood activity) under O₂/CO₂ anaesthesia followed by cervical dislocation. Brain regions (cerebellum, frontal and prefrontal cortex, olfactory bulbs, pituitary, medulla with pons, midbrain, striatum, hypothalamus, hippocampus, and thalamus) and various peripheral tissues (heart, lung, liver, spleen, kidney, muscle, fat, and thymus) were quickly excised and weighted. The activity of [¹²³I] was assayed in a gamma counter, and data was corrected for decay and the amount of radioactivity was presented as percentage of the injected dose, multiplied by the body weight in kilograms, per gram tissue or blood [26]. Selective uptake in the striatum was determined by calculating the ratio of radioactivity in the striatum in relation to that in the cerebellum, since the density of dopamine D2/3 receptor is negligible in this brain area in rats [27].

2.5.2. Blocking Studies Using Storage Phosphor Imaging

To determine whether [¹²³I]-1 binds selectively to D2/3 receptors in vivo, in the following experiments 5 rats received an i.v. injection of the dopamine receptor blocker haloperidol (1 mg/kg) 5 min prior to the injection with [¹²³I]-1 (approximately 37 MBq). A control group () was injected with 0.4 mL buffer 5 min prior to the injection with the radiopharmaceutical. Two hours after the injection of [¹²³I]-1 (this time point was based on the results of the classic biodistribution study; see Results) the rats were sacrificed by bleeding through heart puncture under O₂/CO₂ anaesthesia. The brains were quickly removed and immediately frozen on dry ice. Then the frozen brain was sliced horizontally in 50 μm thick slices. Storage phosphor imaging was done as previously described [28]. In contrast to previous studies, we used a Typhoon FLA 7000 Phosphor imager (GE Healthcare Life Sciences, Uppsala, Sweden) and Hypercassette Amersham Biosciences imaging plates which were scanned at 25 μm pixel size. In this blocking experiment, storage phosphor imaging was used because this offers the opportunity to look into binding in ventral as well as dorsal parts of the striatum. In ventral parts, the expression of dopamine D₃ receptors is higher than in more dorsal parts [19].

3. Results

3.1. Chemistry and Radiochemistry

In Scheme 1 all chemical transformations relevant to this research work are compiled. For preparing the radiolabelled AMC tracer [¹²³I]-1 we have considered and prepared the tri-n-butyl-tin precursors 3 and 4, where 3 is the phenol precursor and 4 is the MOM-protected precursor. These two molecules have been synthesized from their respective iodocounterparts 1 and 2 by reaction with hexa-n-butylditin applying Pd as catalyst. Yields of 3 and 4 after purification using silica chromatography were moderate (ca. 40%).

Next, the stannylated precursors 3 and 4 were assessed in (“cold”) labelling tests. Here, the oxidative iodination conditions that are routinely applied in the radiolabelling of aryl-tin compounds, involving the use of [¹²³I]-NaI in combination with H₂O₂, have been mimicked by replacing [¹²³I]-NaI with regular (“cold”) NaI and by using this regular NaI at a low molar equivalent ratio of approximately 0.1 molequivalents relative to the aryl-tin precursor. These “cold” labelling tests have been executed to determine whether the precursors would produce the desired iodinated products, so product 1 is from precursor 3 and product 2 is from precursor 4. As precursor 3 should give the required compound 1 in a single step, this precursor was preferred. However, after oxidative iodination of 3 we did not find evidence for the formation of useful amounts of desired product 1, as monitored by HPLC-MS analysis. In contrast, we found, apart from the starting material 3, two product peaks with almost equal retention time where both peaks gave the same mass of m/z = 684. We assign these two peaks to the undesired byproducts 5 and 6 (see Scheme 1), where these two byproducts are formed by ortho iodination of the phenol ring. Note that the tri-n-butylstannyl groups in 5 and 6 are unaffected. Gratifyingly, oxidative iodination of precursor 4 only gave the desired product 2 with no trace of ortho iodination, again as monitored by HPLC-MS analysis.

According to the above “cold” labelling tests, the actual radiolabelling procedures have been executed using the MOM-protected precursor 4. In the first step, precursor 4 was oxidatively iodinated using [¹²³I]-NaI to arrive at the intermediate product [¹²³I]-2 that was concentrated on an SPE C18 cartridge and thereafter collected in ethanol. In the second step H₂SO₄ was added to the ethanol solution to achieve deprotection of the MOM group. Heating of the reaction mixture was required to get efficient deprotection in several minutes. Finally, [¹²³I]-1 was purified using a HPLC separation. As we have observed some side product formation in the MOM-deprotection step, we found a moderate overall radiochemical yield. Typically, the overall yield of the labelling process using precursor 4 was 30–35% where the final radiochemical purity of [¹²³I]-1 exceeded 95%.

3.2. Ex Vivo Studies

The biodistribution studies showed that the uptake of [¹²³I]-1 was higher in all brain areas than in blood from 15 min up to 1 h postinjection (p.i.) (Table 1 and Figure 1), suggesting efficient passage of the radiopharmaceutical through the blood-brain barrier. In almost all brain areas, [¹²³I]-1 uptake was higher than in the cerebellum (Tables 1 and 2) from 15 min to 24 h p.i. As can be seen in Table 2 and Figure 1, the mean ratio of striatum/cerebellum binding was about 1.3 and was stable for the period of 30 min to 4 h p.i. In addition, the variation in binding was low in this period; therefore 2 h p.i. was chosen as time point to sacrifice the rats during the subsequent storage phosphor imaging experiment (see Tables 1 and 2 and Figure 1). Uptake in the pituitary, another part of the brain with a relatively high density of dopamine D₂ receptor, was also relatively high.

Table 1: Biodistribution of ¹²³I radioactivity (%ID × kg/g) at different times after intravenous injection of [¹²³I]-1 in male rats ( per group). Data represent mean ± SD.

15 min
30 min
1 h
2 h
3 h
4 h
24 h

Blood
0.291 ± 0.190
0.486 ± 0.291
0.557 ± 0.087
0.446 ± 0.105
0.428 ± 0.082
0.393 ± 0.136
0.081 ± 0.049

Fat
3.080 ± 2.656
0.674 ± 0.102
0.509 ± 0.024
0.365 ± 0.094
0.337 ± 0.065
0.174 ± 0.056
0.016 ± 0.005

Muscle
0.412 ± 0.466
0.363 ± 0.049
0.244 ± 0.023
0.124 ± 0.028
0.119 ± 0.028
0.084 ± 0.041
0.012 ± 0.004

Thymus
0.365 ± 0.507
1.776 ± 0.200
1.591 ± 0.169
1.083 ± 0.454
0.946 ± 0.150
0.815 ± 0.244
0.024 ± 0.001

Heart
1.678 ± 1.142
0.658 ± 0.141
0.962 ± 1.043
0.669 ± 0.348
0.372 ± 0.265
0.180 ± 0.044
0.033 ± 0.005

Lung
3.483 ± 3.534
5.673 ± 2.526
1.622 ± 0.848
0.390 ± 0.302
0.936 ± 0.762
0.573 ± 0.307
0.040 ± 0.005

Liver
1.316 ± 0.773
2.644 ± 0.361
2.470 ± 0.449
2.713 ± 0.487
2.387 ± 1.400
3.164 ± 0.824
0.260 ± 0.064

Spleen
2.428 ± 1.971
1.270 ± 0.282
0.749 ± 0.093
0.266 ± 0.047
0.284 ± 0.092
0.166 ± 0.087
0.022 ± 0.003

Kidney
1.618 ± 0.774
1.735 ± 0.353
1.770 ± 0.302
1.081 ± 0.154
1.336 ± 0.175
1.005 ± 0.397
0.150 ± 0.026

Pituitary
1.401*
3.367 ± 1.033
1.561 ± 0.538
0.918 ± 0.632
0.548 ± 0.149
0.307 ± 0.056
0.082 ± 0.006

Olfactory b.
0.445 ± 0.439
1.325 ± 0.402
0.631 ± 0.036
0.218 ± 0.025
0.234 ± 0.087
0.112 ± 0.043
0.020 ± 0.001

Frontal cortex
2.567 ± 1.933
2.329 ± 0.904
0.722 ± 0.061
0.223 ± 0.028
0.232 ± 0.095
0.109 ± 0.057
0.024 ± 0.002

Striatum
1.231 ± 1.299
1.947 ± 0.666
0.779 ± 0.037
0.226 ± 0.034
0.232 ± 0.065
0.101 ± 0.051
0.027 ± 0.010

Hypothalamus
1.335 ± 0.766
1.699 ± 0.526
0.747 ± 0.111
0.218 ± 0.036
0.233 ± 0.070
0.114 ± 0.051
0.027 ± 0.005

Thalamus
1.556 ± 1.015
1.978 ± 0.618
0.779 ± 0.049
0.234 ± 0.037
0.279 ± 0.091
0.114 ± 0.047
0.033 ± 0.006

Hippocampus
0.826 ± 0.475
2.155 ± 0.675
0.866 ± 0.089
0.255 ± 0.040
0.230 ± 0.085
0.093 ± 0.059
0.014 ± 0.001

Midbrain
3.566 ± 4.660
1.715 ± 0.577
0.754 ± 0.040
0.229 ± 0.046
0.214 ± 0.062
0.098 ± 0.059
0.020 ± 0.003

Pons/medulla
1.188 ± 0.587
1.486 ± 0.274
0.761 ± 0.040
0.237 ± 0.045
0.229 ± 0.066
0.106 ± 0.057
0.017 ± 0.001

Cerebellum
0.858 ± 0.384
1.496 ± 0.478
0.627 ± 0.035
0.196 ± 0.037
0.178 ± 0.061
0.087 ± 0.043
0.014 ± 0.002

At this time point and in this brain area, only 1 sample was available.

Table 2: Brain areas to cerebellum uptake ratios at different times after intravenous injection of [¹²³I]-1.

15 min
30 min
1 h
2 h
3 h
4 h
24 h

Pituitary/cereb.
1.157*
2.262 ± 0.233
2.502 ± 0.883
4.399 ± 2.113
3.352 ± 1.490
3.570 ± 2.544
6.021 ± 0.577

Olfactory b./cereb.
0.431 ± 0.330
0.893 ± 0.067
1.007 ± 0.050
1.125 ± 0.089
1.314 ± 0.150
1.333 ± 0.124
1.444 ± 0.163

Frontal cortex/cereb.
2.962 ± 1.817
1.543 ± 0.142
1.154 ± 0.095
1.145 ± 0.079
1.315 ± 0.360
0.865 ± 0.580
1.818 ± 0.372

Striatum/cereb.
1.455 ± 1.265
1.294 ± 0.061
1.246 ± 0.103
1.155 ± 0.069
1.331 ± 0.126
1.156 ± 0.080
2.023 ± 0.872

Hypothalamus/cereb.
1.512 ± 0.546
1.139 ± 0.014
1.189 ± 0.132
1.116 ± 0.085
1.326 ± 0.053
1.332 ± 0.103
1.989 ± 0.574

Thalamus/cereb.
1.670 ± 0.908
1.325 ± 0.074
1.243 ± 0.042
1.200 ± 0.067
1.582 ± 0.101
1.351 ± 0.175
2.473 ± 0.599

Hippocampus/cereb.
0.870 ± 0.303
1.479 ± 0.466
1.390 ± 0.210
1.301 ± 0.047
1.294 ± 0.112
1.035 ± 0.114
1.031 ± 0.090

Midbrain/cereb.
3.712 ± 4.715
1.144 ± 0.051
1.207 ± 0.109
1.168 ± 0.080
1.224 ± 0.090
1.097 ± 0.086
1.426 ± 0.204

Pons/medulla/cereb.
1.470 ± 0.520
1.036 ± 0.212
1.218 ± 0.109
1.205 ± 0.016
1.310 ± 0.114
1.214 ± 0.133
1.278 ± 0.211

At this time point and in this brain area, only 1 sample was available.

Figure 1: Results of biodistribution studies in Wistar rats. Uptake ratios of uptake in several brain areas compared to cerebellum uptake at different times after intravenous injection of [¹²³I]-1.

Regarding the [¹²³I]-1 uptake in the peripheral organs and tissues, initially an intense uptake was seen in fat, muscle, heart, and spleen (15 min) followed by a washout (at 30 min and later, Table 1). However in lung tissue, thymus, and liver, uptake peaked at 30 min. In the heart and kidney, uptake peaked at 1 h. In the lung, liver, and kidney uptake remained more or less stable for the 1 h–4 h time period, with a second peak of uptake in the lung and kidney at 3 h and in the liver at 4 h. Also in blood a second peak was observed after 1 h p.i.

In the storage phosphor imaging experiments, no specific striatal binding was observed for [¹²³I]-1 (Figure 2). Interestingly, high uptake in white matter was observed. In addition, no specific binding was visualized in other brain areas including the globus pallidus.

(a)

(b)

Figure 2: Ex vivo storage phosphor imaging slice experiment of [¹²³I]-1 (2 h p.i.). (a) This rat received 1 mg/kg haloperidol i.v. 5 min prior to injection of the radioligand. (b) Control rat received saline 5 min i.v. prior to injection.

4. Discussion

Currently we are developing new agonist radiopharmaceuticals to visualize dopamine D2/3 receptors in their high-affinity state in the human brain for centers without an on-site cyclotron. Therefore a series of ligands were synthesized and tested in vitro [24]. On the basis of promising in vitro results, one of the assayed compounds (i.e., compound 1) was selected as a potential SPECT ligand. In this work we show the successful labelling of compound 1 with iodine-123, as well as the ex vivo characterization in the rat.

Molecules 3 and 4 were prepared as potential precursors to produce [¹²³I]-1, and “cold” labelling tests using NaI and oxidative conditions were conducted to assess the usefulness of these two precursors. For molecule 3 undesired ortho iodination was shown to be preferred over iodination at the activated para-aryl-stannyl position. Indeed, the phenol ring in molecule 3 is quite electron rich and is therefore prone to undergo ortho iodination. In contrast, the MOM-protected molecule 4 only showed iodination at the activated para-aryl-stannyl position. Apparently, MOM-protection deactivates the phenol ring to such an extent that ortho iodination is prohibited and that iodination at the tri-n-butyltin site becomes favored and can occur exclusively.

Although the oxidative ortho iodination of precursor 3 was not desired for this current study, it can be considered for the preparation of the two prospective labelled compounds [¹²³I]-8 and [¹²³I]-9 (see Scheme 2) by using the simple precursor (R) N-[7-hydroxychroman-2-yl]-methyl benzyl amine (7). Molecule 7 has previously been reported by Mewshaw and coworkers [25]; in the same work by Mewshaw et al. it has been shown that chlorination at the ortho 6-position of the phenol ring of AMC 7 does affect the affinity for the D2/3 receptor somewhat, but the chlorinated species still displays a high-affinity and a high selectivity towards D2/3 receptor as compared to binding to other receptors. We have nevertheless not pursued the preparation of [¹²³I]-8 and [¹²³I]-9, as we anticipate that the AMC pharmacophore will be affected by the introduction of the large iodogroup ortho to the hydroxy moiety. Furthermore, and as a more practically inclined notion, it may be difficult to effectively separate [¹²³I]-8 and [¹²³I]-9, as both molecules will be formed in the iodination step and as 8 and 9 will have very similar chromatographic retention behavior.

Scheme 2: Hypothetical and prospective oxidative radiolabelling of AMC molecule 7 to the potential tracers [¹²³I]-8 and [¹²³I]-9. For 8 and 9, labelling occurs at the 2- and 6-position of the phenol ring, respectively.

The radiosynthesis of [¹²³I]-1 proceeded in two steps from precursor 4, giving a moderate radiochemical yield (30–35%) and a good radiochemical purity (>95%). We have so far not pursued further improvements of this radiolabelling process, as the acquired radiochemical purity was considered acceptable for the ex vivo testing of [¹²³I]-1, while the radiochemical yield, although moderate, nevertheless permitted the preparation of sufficient amounts of radiolabelled compound for the execution of all planned tests.

In biodistribution studies, it was found that [¹²³I]-1 had initially a higher uptake in the brain than in the blood suggesting rapid passage of the blood-brain barrier which is one of the crucial properties of a potential radiopharmaceutical for receptors in brain [29, 30].

Further biodistribution data showed that, in almost all areas of the brain, including the striatum, the [¹²³I]-1 uptake was higher than in the cerebellum. However in the storage phosphor imaging experiments it appeared that no binding in the striatum was blocked by the dopamine receptor antagonist haloperidol, suggesting absence of specific displaceable binding to dopamine D2/3 receptor. The discrepancy between the biodistribution and storage phosphor imaging studies may be explained as follows. [¹²³I]-1 does bind in vivo to receptors that are expressed outside the cerebellum but are not blocked by haloperidol. Since haloperidol binds not only to D2/3/4 receptors but also to the sigma-1 sites [31] and -adrenoceptors [32], it is unlikely that [¹²³I]-1 binds to these receptors in vivo. However, further evaluations are needed to identify the receptor to which this novel radiotracer may bind. Nevertheless, the radiotracer may be too lipophilic to visualize D2/3 receptor in vivo, and consequently our findings do not support the start of further studies in humans.

In the storage phosphor imaging studies it was shown that [¹²³I]-1 binds to white matter, which suggests that the tracer has a relatively high lipophilicity. In line with this finding is the high uptake in peripheral fat tissue. This finding was unexpected since the calculated lipophilicity () was within the proper range for developing a radiopharmaceutical [29, 30]. However, also in other studies the calculated lipophilicity did not always predict the success of a novel radiotracer [29] and calculated values can sometimes deviate from experimentally determined values [33]. In the biodistribution experiment a second peak was observed in the uptake of iodine-123 in blood at 1 h; this could be explained by a reabsorption in the duodenum of iodinated metabolites formed in the liver that are secreted in bile fluid (enterohepatic circulation). The fact that 1 is excreted in bile and undergoes the hepatic circulation may also confirm that it has high fat solubility and thus a high lipophilicity.

Another hypothetical reason that we observed no specific binding of [¹²³I]-1 in the brain might be active efflux of [¹²³I]-1 through, for example, a PgP pump. However, we believe that this is unlikely since we recently observed that several other compounds of our AMCs showed to be no substrates for this efflux pump (unpublished data). Also, we cannot exclude the fact that radiolabelled metabolites were formed that have passed the blood-brain barrier. However, for a similar compound (AMC20), we found that 95% of the radioactivity from a brain tissue extract (35 min after injection) was intact ¹⁸F-AMC20 and that radiometabolites of ¹⁸F-AMC20 were hydrophilic and did not pass the blood-brain barrier [34]. Since our present compound has a similar structure, we believe that it is unlikely that formation of radiometabolites will have significantly influenced the results.

The in vitro experiments showed that the compound 1 binds with high-affinity to dopamine D₄ receptor. However, the storage phosphor imaging studies also showed no specific binding in the D₄-rich globus pallidus. Given that this tracer did not bind in vivo to the other D₂ receptor-like receptors (i.e., D2/3 receptor), it would have been unexpected that this tracer binds selectively to the D₄ receptor in vivo. However, only future blocking studies using selective dopamine D₄ receptor agents can prove this postulate.

In our previous study [24] where we explored the new group of potential agonist tracers on in vitro properties, two of the most promising fluorine containing compounds were fluorine-18 labelled successfully. Both displayed specific binding to dopamine D2/3 receptors in vitro in rat brain slices in autoradiography experiments, which encourages further in vivo evaluations, including storage phosphor imaging.

5. Conclusion

We have successfully prepared the radiolabelled D2/3 receptor agonist [¹²³I]-1. Although this novel radiotracer specifically binds to D2/3 receptors in vitro, its signal-to-noise ratios in rodents were low and no specific binding was observed which prevent further use in humans. Particularly, the performed biodistribution studies suggested higher binding in the D2/3 receptor-rich striatum than in brain areas devoid of D2/3 receptors, while the final storage phosphor imaging studies showed no selective binding of [¹²³I]-1 to central D2/3 receptors in rats. Still, this new scaffold may be a good reference and starting point for further studies aiming at the development of in-demand D2/3 receptor agonist SPECT tracers suitable for in vivo application in humans.

Abbreviations

AMC: | 2-Aminomethylchroman
moleqs: | Molar equivalents
MOM: | Methoxymethoxy
PDA: | Photodiode array
TOH: | At the time of handling.

Conflict of Interests

Anton G. M. Janssen and Peter A. van Doremalen are employees of GE Healthcare, a company marketing the DA D2/3 receptor antagonist radiopharmaceutical [¹²³I]-IBZM. Martin C. Michel is an employee of Boehringer Ingelheim, a company marketing the DA D₂ agonist pramipexole. Jan Booij is a consultant at GE Healthcare. The other authors declare that they have no conflict of interests.

Acknowledgments

Dr. J. A. J. M. (Jef) Vekemans, Eindhoven University of Technology (TU/e), is thanked for his advice on synthetic design. Professor E. W. (Bert) Meijer (TU/e and ICMS Eindhoven) is thanked for enabling the execution of the preparative synthetic part of the presented research. This work has been supported by a grant from the Dutch Technology Foundation STW (Grant 10127).

References

J. Booij, G. Tissingh, A. Winogrodzka, and E. A. Van Royen, “Imaging of the dopaminergic neurotransmission system using single-photon emission tomography and positron emission tomography in patients with parkinsonism,” European Journal of Nuclear Medicine, vol. 26, no. 2, pp. 171–182, 1999.

S. Kapur and D. Mamo, “Half a century of antipsychotics and still a central role for dopamine D₂ receptors,” Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 27, no. 7, pp. 1081–1090, 2003.

N. D. Volkow, J. S. Fowler, G.-J. Wang, and J. M. Swanson, “Dopamine in drug abuse and addiction: results from imaging studies and treatment implications,” Molecular Psychiatry, vol. 9, no. 6, pp. 557–569, 2004.

S. von Campenhausen, B. Bornschein, R. Wick et al., “Prevalence and incidence of Parkinson's disease in Europe,” European Neuropsychopharmacology, vol. 15, no. 4, pp. 473–490, 2005.

R. B. Goldstein, D. A. Dawson, S. Patricia Chou, and B. F. Grant, “Sex differences in prevalence and comorbidity of alcohol and drug use disorders: results from wave 2 of the national epidemiologic survey on alcohol and related conditions,” Journal of Studies on Alcohol and Drugs, vol. 73, no. 6, pp. 938–950, 2012.

J. C. Stoof and J. W. Kebabian, “Opposing roles for D-1 and D-2 dopamine receptors in efflux of cyclic AMP from rat neostriatum,” Nature, vol. 294, no. 5839, pp. 366–368, 1981.

P. G. Strange, “New insights into dopamine receptors the central nervous system,” Neurochemistry International, vol. 22, no. 3, pp. 223–236, 1993.

D. R. Sibley, A. de Lean, and I. Creese, “Anterior pituitary dopamine receptors. Demonstration of interconvertible high and low affinity states of the D-2 dopamine receptor,” Journal of Biological Chemistry, vol. 257, no. 11, pp. 6351–6361, 1982.

C. L. Chio, M. E. Lajiness, and R. M. Huff, “Activation of heterologously expressed D3 dopamine receptors: comparison with D2 dopamine receptors,” Molecular Pharmacology, vol. 45, no. 1, pp. 51–60, 1994.

P. Seeman, D. Weinshenker, R. Quirion et al., “Dopamine supersensitivity correlates with D2High states, implying many paths to psychosis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 9, pp. 3513–3518, 2005.

J.-P. Van Wieringen, J. Booij, V. Shalgunov, P. Elsinga, and M. C. Michel, “Agonist high- and low-affinity states of dopamine D2 receptors: methods of detection and clinical implications,” Naunyn-Schmiedeberg's Archives of Pharmacology, vol. 386, no. 2, pp. 135–154, 2013.

N. R. Zahniser and P. B. Molinoff, “Effect of guanine nucleotides on striatal dopamine receptors,” Nature, vol. 275, no. 5679, pp. 453–455, 1978.

P. Seeman, J. Schwarz, J.-F. Chen et al., “Psychosis pathways converge via D2High dopamine receptors,” Synapse, vol. 60, no. 4, pp. 319–346, 2006.

S. R. George, M. Watanabe, and P. Seeman, “Dopamine D2 receptors in the anterior pituitary: a single population without reciprocal antagonist/agonist states,” Journal of Neurochemistry, vol. 44, no. 4, pp. 1168–1177, 1985.

S. J. Finnema, B. Bang-Andersen, H. V. Wikström, and C. Halldin, “Current state of agonist radioligands for imaging of brain dopamine D2/D3 receptors in vivo with positron emission tomography,” Current Topics in Medicinal Chemistry, vol. 10, no. 15, pp. 1477–1498, 2010.

N. Ginovart, M. Willeit, P. Rusjan et al., “Positron emission tomography quantification of [¹¹C]-(+)-PHNO binding in the human brain,” Journal of Cerebral Blood Flow & Metabolism, vol. 27, no. 4, pp. 857–871, 2007.

R. Narendran, W. G. Frankle, N. S. Mason et al., “Positron emission tomography imaging of D2/3 agonist binding in healthy human subjects with the radiotracer [¹¹C]-N-propyl- norapomorphine: preliminary evaluation and reproducibility studies,” Synapse, vol. 63, no. 7, pp. 574–584, 2009.

T. Otsuka, H. Ito, C. Halldin et al., “Quantitative PET analysis of the dopamine D₂ receptor agonist radioligand ¹¹C-(R)-2-CH₃O-N-n-propylnorapomorphine in the human brain,” Journal of Nuclear Medicine, vol. 50, no. 5, pp. 703–710, 2009.

R. Narendran, N. S. Mason, C. M. Laymon et al., “A comparative evaluation of the dopamine D2/3 agonist radiotracer [¹¹C](-)-N-propyl-norapomorphine and antagonist [¹¹C]raclopride to measure amphetamine-induced dopamine release in the human striatum,” Journal of Pharmacology and Experimental Therapeutics, vol. 333, no. 2, pp. 533–539, 2010.

P. Shotbolt, A. C. Tziortzi, G. E. Searle et al., “Within-subject comparison of [¹¹C]-(+)-PHNO and [¹¹C]raclopride sensitivity to acute amphetamine challenge in healthy humans,” Journal of Cerebral Blood Flow and Metabolism, vol. 32, no. 1, pp. 127–136, 2012.

R. Narendran, D.-R. Hwang, M. Slifstein et al., “In vivo vulnerability to competition by endogenous dopamine: comparison of the D₂ receptor agonist radiotracer (−)-N-[¹¹C]propyl-norapomorphine ([¹¹C]NPA) with the D₂ receptor antagonist radiotracer [¹¹C]-raclopride,” Synapse, vol. 52, no. 3, pp. 188–208, 2004.

N. Ginovart, L. Galineau, M. Willeit et al., “Binding characteristics and sensitivity to endogenous dopamine of [¹¹C]-(+)-PHNO, a new agonist radiotracer for imaging the high-affinity state of D₂ receptors in vivo using positron emission tomography,” Journal of Neurochemistry, vol. 97, no. 4, pp. 1089–1103, 2006.

S. J. Finnema, V. Stepanov, R. Nakao et al., “¹⁸F-MCL-524, an ¹⁸F-labeled dopamine D2 and D3 receptor agonist sensitive to dopamine: a preliminary PET study,” Journal of Nuclear Medicine, vol. 55, no. 7, pp. 1164–1170, 2014.

J.-P. Van Wieringen, V. Shalgunov, H. M. Janssen et al., “Synthesis and characterization of a novel series of agonist compounds as potential radiopharmaceuticals for imaging dopamine D2/3 receptors in their high-affinity state,” Journal of Medicinal Chemistry, vol. 57, no. 2, pp. 391–410, 2014.

R. E. Mewshaw, J. Kavanagh, G. Stack et al., “New generation dopaminergic agents. 1. Discovery of a novel scaffold which embraces the D₂ agonist pharmacophore. Structure-activity relationships of a series of 2-(aminomethyl)chromans,” Journal of Medicinal Chemistry, vol. 40, no. 26, pp. 4235–4256, 1997.

J. Booij, G. Andringa, L. J. M. Rijks et al., “[¹²³I]FP-CIT binds to the dopamine transporter as assessed by biodistribution studies in rats and SPECT studies in MPTP-lesioned monkeys,” Synapse, vol. 27, pp. 183–190, 1997.

B. Kiss, F. Horti, and A. Bobok, “In vitro and in vivo comparison of [³H](+)-PHNO and [3H]raclopride binding to rat striatum and lobes 9 and 10 of the cerebellum: a method to distinguish dopamine D₃ from D₂ receptor sites: a method to distinguish dopamine D₃ from D₂ receptor sites,” Synapse, vol. 65, no. 6, pp. 467–478, 2011.

R. J. J. Knol, K. de Bruin, J. de Jong, B. L. F. van Eck-Smit, and J. Booij, “In vitro and ex vivo storage phosphor imaging of short-living radioisotopes,” Journal of Neuroscience Methods, vol. 168, no. 2, pp. 341–357, 2008.

M. Laruelle, M. Slifstein, and Y. Huang, “Relationships between radiotracer properties and image quality in molecular imaging of the brain with positron emission tomography,” Molecular Imaging and Biology, vol. 5, no. 6, pp. 363–375, 2003.

D. F. Wong and M. G. Pomper, “Predicting the success of a radiopharmaceutical for in vivo imaging of central nervous system neuroreceptor systems,” Molecular Imaging and Biology, vol. 5, no. 6, pp. 350–362, 2003.

E. J. Cobos, E. D. Pozo, and J. M. Baeyens, “Irreversible blockade of sigma-1 receptors by haloperidol and its metabolites in guinea pig brain and SH-SY5Y human neuroblastoma cells,” Journal of Neurochemistry, vol. 102, no. 3, pp. 812–825, 2007.

W. K. Kroeze, S. J. Hufeisen, B. A. Popadak et al., “H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs,” Neuropsychopharmacology, vol. 28, no. 3, pp. 519–526, 2003.

R. N. Waterhouse, “Determination of lipophilicity and its use as a predictor of blood-brain barrier penetration of molecular imaging agents,” Molecular Imaging & Biology, vol. 5, no. 6, pp. 376–389, 2003.

V. Shalgunov, J. P. van Wieringen, H. M. Janssen et al., “Synthesis and evaluation in rats of the dopamine D2/3 receptor agonist ¹⁸F-AMC20 as potential radioligand for PET,” Journal of Nuclear Medicine, 2014.